New - sinochem cephalosporin antibiotic use intermediates as one of the most marketization of industry, the market competition is fierce. However, shanxi high-tech private enterprise new hd pharmaceutical chemical Co., LTD with by the master of core technology, breaking international giant monopoly, make its antibiotic medicine intermediates products accounted for EPCP HO - 60 per cent of global market share, becoming China's important material and the largest domestic cephalosporin antibiotic intermediates production base.

Cephalosporins antibiotics during anti-infection medicine market for high share, and related intermediates also in fine chemical industry occupies an important position. In the past, pharmaceutical intermediates mostly by pharmaceutical enterprise, with own production social division of labor, deeply and production technology progress, pharmaceutical industry will be some pharmaceutical intermediates relayed to the chemical enterprise production, pharmaceutical intermediates were mostly high added value, the lucrative fine chemical products, to the chemical enterprise development pharmaceutical intermediates products created enormous business opportunities. New hd company technology research and development centers director tells a reporter, if break developed countries cephalosporin antibiotic use intermediate technology monopoly, China cephalosporin antibiotic use intermediates can give consumer brings huge welfare.

Cephalosporin antibiotic use intermediates product features is USES single-minded, demanding. Domestic cephalosporin intermediates market after a period of development, quantity by a limited amount, manufacturers bysouthing north distribution, more and more intense market competition, the price dropped substantially, the enterprise glides struggling. Shanxi new hd company chairman SuBinLin therefore put forward: "domestic antibiotics intermediates sallies only rely on technological innovation.

The company has long been dedicated to technical reform and innovation. The technical center adopt well-paid, technical contribution, benefit commission etc incentive mechanism, by way of multi-channel expected talent exchange 60/10000. At present, the company has established by doctors, masters, bachelor, college students as the main body of the staff and technical team. They uphold "producing one generation, developing generation, reserves generation, conception generation" innovative ideas, and shanxi and chemical engineering to set up a joint innovation drugs and molecular engineering r&d center, and shanxi university, shanxi medical planning design institute established the good cooperation relations, has developed to produce cephalosporin drugs intermediates etc series products.

Up to now, the company has built many pharmaceutical intermediates production lines, the annual production scale aggregated 800 tons, nearly three years undertake research and development projects completed at or above the provincial level 5. Its main products include HO - EPCP, EPCP, double oxygen 22.6%, two benjia methadone hydrazone, three different iodine phthalocyanine acid, three different iodine phthalocyanine acid carbonyl chlorides, etc. Among them, HO - EPCP, double oxygen ofloxacin production scale, the first domestic production technology leading international. Our products are sold to Beijing, Shanghai and southwest, leading products of similar products in the domestic market share 85%. Meanwhile, the company actively explore international market, HO - EPCP, double oxygen ofloxacin for exporting products such as Italy, South Korea, Japan, etc, total market share Asian markets 40%. In addition, new hd chemical Co., LTD. New products accounted for 70% of the proportion, including flagship product HO - EPCP pharmaceutical intermediates already occupied global 60% share.

At present, shanxi new hd pharmaceutical chemical Co., LTD is implementing produces 20 tons of third-generation cephalosporins antibiotics beta extended-spectrum beta-lactamase-producing series of intermediate products technical renovation programs. The project total investment of 80 million yuan, of which fixed assets investment of 50 million yuan. After the completion of the project, will increase the sales income is 600 million yuan, profit 90 million yuan.